pirtobrutinib: the next generation of btk inhibitors
Published 3 years ago • 1.1K plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
3:31
tolerability of next-generation btk inhibitors: acalabrutinib, zanubrutinib and pirtobrutinib
-
1:10
the role of next-generation btk inhibitors in the treatment of cll
-
2:02
the benefits of next-generation btk inhibitors in cll
-
1:08
phase i/ii bruin study: pirtobrutinib in patients intolerant to a covalent btk inhibitor
-
2:57
second-generation btk inhibitors and their clinical impact
-
2:41
advances in the treatment and prognosis of ttp
-
2:57
selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in cll
-
2:40
btk inhibitors for r/r mcl: current uses and insights from the vipor study
-
1:57
the pharmacokinetics of pirtobrutinib
-
1:10
next-generation btk inhibitors and their role in the cll treatment landscape
-
1:27
advances in btk and bcl2 inhibitors for cll
-
1:21
overview of the role of non-covalent btk inhibitors in the era of covalent btk inhibitors
-
0:52
rilzabrutinib: a novel promising btk inhibitor being explored in itp
-
1:30
developments in the use of different classes of btk inhibitors for cll treatment
-
1:56
updated results of phase i/ii bruin study: pirtobrutinib in covalent btk inhibitor pretreated mcl
-
1:32
genomic evolution & resistance to pirtobrutinib in covalent btk inhibitor pre-treated cll
-
1:14
evaluating the role of btk inhibitors in cll
-
1:30
the use of pirtobrutinib in richter's transformation: data from the bruin trial
-
3:01
updates from the bruin study – long-term safety of pirtobrutinib in r/r mcl
-
1:35
pirtobrutinib in r/r fl: results from the bruin study
-
2:31
the value of btk inhibitors in cll & the future of acalabrutinib in this disease
-
1:18
the impact of the approval of pirtobrutinib on the treatment landscape for patients with cll